Aristides Capital LLC Purchases New Position in Progyny, Inc. (NASDAQ:PGNY)

Aristides Capital LLC bought a new position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 14,200 shares of the company's stock, valued at approximately $245,000.

Several other hedge funds and other institutional investors have also bought and sold shares of PGNY. Charles Schwab Investment Management Inc. boosted its position in shares of Progyny by 0.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 673,446 shares of the company's stock valued at $11,287,000 after purchasing an additional 4,007 shares in the last quarter. State Street Corp grew its position in shares of Progyny by 4.5% during the 3rd quarter. State Street Corp now owns 3,113,654 shares of the company's stock worth $52,185,000 after buying an additional 134,861 shares during the period. Wolverine Trading LLC increased its stake in shares of Progyny by 131.5% in the 3rd quarter. Wolverine Trading LLC now owns 19,677 shares of the company's stock valued at $331,000 after acquiring an additional 11,177 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Progyny by 4.0% during the 3rd quarter. Wellington Management Group LLP now owns 430,300 shares of the company's stock valued at $7,212,000 after acquiring an additional 16,638 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new position in Progyny during the third quarter worth $469,000. Institutional investors and hedge funds own 94.93% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. BTIG Research upgraded shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective on the stock in a report on Monday, March 31st. Bank of America increased their price target on Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday, February 11th. Canaccord Genuity Group boosted their price objective on Progyny from $17.00 to $23.00 and gave the company a "hold" rating in a report on Friday, February 28th. Finally, JPMorgan Chase & Co. increased their target price on Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. Eight equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $23.64.

Remove Ads

Progyny Stock Up 0.4 %

Progyny stock traded up $0.08 during mid-day trading on Friday, reaching $22.34. 855,876 shares of the company's stock were exchanged, compared to its average volume of 1,729,568. The business's fifty day simple moving average is $22.01 and its 200 day simple moving average is $18.68. Progyny, Inc. has a one year low of $13.39 and a one year high of $34.92. The firm has a market capitalization of $1.91 billion, a PE ratio of 38.52, a P/E/G ratio of 2.39 and a beta of 1.33.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.